Eisai Co., Ltd., a Tokyo-based pharmaceutical company, has recently revealed that it will be presenting its presentation on a series of abstracts pertaining to its in-house discovered eribulin mesylate and lenvatinib mesylate at the American Society of Clinical Oncology (ASCO) from May 29 – 31, 2020.
According to reliable sources, the company will be focusing on presenting the final results from two of its studies on the combination therapy of lenvatinib with KEYTRUDA®, Merck’s anti-PD-1 antibody.
Reportedly, the first study focuses on the oral presentation of Study 111/ KEYNOTE-146’s mRCC (metastatic renal cell carcinoma) cohort, while the second one would be a poster discussion presentation of Study 116/KEYNOTE-524’s first-line treatment for unresectable hepatocellular carcinoma.
Earlier in March 2018, both the companies, Merck & Co., Inc. and Eisai, had entered into a strategic partnership through an affiliate for the global co-commercialization and co-development of lenvatinib.
Prior to this news, Eisai had managed to make headlines when it announced that was awarded as the “Most Honored Company” by the Institutional Investor, an American financial information magazine. Evidently, the company has also bagged the first rank in the Biotechnology & Pharmaceuticals sector.
Sources cite that this selection was based on Eisai’s previous awards namely, the first position in classes like "Best CFOs" and "Best CEOs" in the sector.
Over the years, Eisai’s corporate philosophy has been simple. It has intended to offer first thought to patients and their members while increasing the benefits of healthcare and addressing the diverse healthcare needs across the globe.
In order to adhere to these philosophies, the firm would respect the rights of investors and shareholders, engage in all those IR activities that contribute to the development of corporate value and ensure transparency and fairness of management.
Source Credit: https://www.eisai.com/news/2020/news202020.html